This article focuses on why the antiphospholipid antibodies and recurrent miscarriages are not correlated. As the name suggests, this type of antibodies targets the phospholipids in the membrane of cells, which triggers an autoimmune response, leading to conditions such as Lupus. This theory also suggests that it is the main contributing reason as to why recurrent miscarriages occur amongst a certain a group of women.
These women are identified to have higher levels of AP-Antibodies, which then target the embryo during its early stages, leading to an autoimmune response, causing a miscarriage. This is the supposed conclusion this mechanism proposes that causes recurrent immunological miscarriage.
In the patents of US7674590B2, it is discovered upon close examination that women who undergo recurrent immunological miscarriage, their embryos are missing a crucial component known as the fibronectin layer. The fibronectin layer is an immunological barrier due to its ability of selective diffusion, only allowing small molecules such as O2, H2O, amino acids, fats etc, and does not allow large proteins to go through. This function alone protects the fetus from the maternal immune system, so AP-Antibodies is not the actual cause of recurrent immunological miscarriages. Because they are unable to diffuse through the fibronectin layer, unable to make any contact to the growing embryo.
As to why this immunological miscarriage occurs, this is due to the absence or damaged fibronectin layer, directly exposing the embryo to maternal immune system, where maternal lymphocytes attacks and eliminates the embryo (the antigen), causing embryonic demise and subsequently: an immunological miscarriage. Dr Chen Fenglin has discovered that the culprit behind the damaged or absent fibronectin is none other than: anti-embryonic antibodies, present in the woman who have experienced this immunological miscarriage. Antai Hospital not only has determined the core reason behind this condition, but we also provide an accurate and effective immunotherapy with over 95% success rate with over 400-500 patients a year. Click here to read more about these anti-embryonic antibodies or our immunotherapy.
This discovery has been patented and awarded in 30 over countries in regions of the USA, European Union, and China. Our immunotherapy can be verified by our thousand of patients who can provide you with their personal testimonies. And in rare cases of failure, we offer full refund guaranteed for this treatment. Arrange a consultation with us today.
Read more about our treatment and its mechanism in our internationally patented papers:
https://patents.google.com/patent/US7674590B2/en?oq=us7674590b2
https://patents.google.com/patent/EP1722225B1/en?oq=us7674590b2
https://patents.google.com/patent/CN100504388C/en?oq=us7674590b2